Market Overview

Chelsea Therapeutics Reports FDA Acceptance of Northera NDA Resubmission, PDUFA Date Set at Feb. 14, 2014

Related CHTP
The Top 25 Analysts On Wall Street
Chelsea Therapeutics Reports Clinical Trial Data on NORTHERA

Chelsea Therapeutics International, Ltd. (Nasdaq: CHTP) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the New Drug Application (NDA) resubmission seeking approval to market NORTHERA™ (droxidopa), an orally active synthetic precursor of norepinephrine, for the treatment of symptomatic neurogenic orthostatic hypotension (NOH). The resubmission includes additional information to resolve certain technical deficiencies previously noted by the Agency.  The FDA has deemed the current resubmission a complete response to its March 28, 2012 Complete Response Letter and assigned a new Prescription Drug User Fee Act (PDUFA) goal date of February 14, 2014.

Northera was previously granted Orphan Drug Designation and received Fast Track designation from the FDA.  Fast Track designation is designed to facilitate the review of products that address serious or potentially life-threatening conditions for which there is an unmet medical need.

Posted-In: News FDA


Related Articles (CHTP)

View Comments and Join the Discussion!